Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Identifying Biomarkers for Predicting Paclitaxel Response

Oncotarget

March 28, 2024
In this research perspective, researchers discuss causal and correlative approaches to identify potential biomarkers for predicting paclitaxel response. continue reading »

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

Oncotarget

March 27, 2024
PRESS RELEASE: On March 19, 2024, a new research paper was published in Oncotarget, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” continue reading »

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

News

March 25, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” continue reading »

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

News

March 20, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.” continue reading »

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

News

March 19, 2024
PRESS RELEASE: On March 15, 2024, a new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., in Oncotarget, entitled, “From osimertinib to preemptive combinations.” continue reading »